Clinical Trials Directory

Trials / Unknown

UnknownNCT05510648

Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis

The Effect of High-intensity Laser Therapy in Knee Osteoarthritis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Necmettin Erbakan University · Academic / Other
Sex
All
Age
45 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the effects of high intensity laser therapy (HILT) on range of motion, pain, quality of life, muscle strength and femoral cartilage thickness in patients with knee osteoarthritis.

Detailed description

Patients who are admitted and diagnosed with knee osteoarthritis based on anamnesis, physical examination and imaging methods are included in the study.

Conditions

Interventions

TypeNameDescription
OTHERhigh-intensity laser therapyA total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
OTHERsham high-intensity laser therapyHotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.

Timeline

Start date
2022-09-25
Primary completion
2022-09-25
Completion
2022-11-25
First posted
2022-08-22
Last updated
2022-09-28

Source: ClinicalTrials.gov record NCT05510648. Inclusion in this directory is not an endorsement.